Cover Image
市場調查報告書

全球癌症疫苗市場與開發平台分析

Global Cancer Vaccines Market & Pipeline Analysis

出版商 KuicK Research 商品編碼 311929
出版日期 內容資訊 英文 864 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症疫苗市場與開發平台分析 Global Cancer Vaccines Market & Pipeline Analysis
出版日期: 2014年09月08日 內容資訊: 英文 864 Pages
簡介

癌症疫苗,是未發現有效治療方法的各種類型癌症之治療有力選項,而受到注目。癌症疫苗大致區分為,強化人體本來具有的防禦功能,治療癌症患者的治療用疫苗,和在健康的人體內防止癌症成長的預防用疫苗。現在成為製藥公司主要收入來源的是預防用疫苗,治療用疫苗的市場還是未觸及的狀態,不過如果今後各國的監督機關加速核准流程、製藥公司大幅度增強研究開發投資的話,整體市場也可能急速擴大。最近剛誕生的癌症疫苗,臨床試驗標準化困難,加上有效性定量化的標準不完全,作用機制與傳統的治療方法不同,而無法適用於化療和放射線治療、手術等對應的標準,不過已經有許多的研究人員致力於這個問題,不久的將來將會找到解決的辦法。

本報告提供全球癌症疫苗市場詳細分析、今後展望、現在研究開發推動的產品資訊、美食品藥物管理局(FDA)的法律規範、各主要企業公司概要和產品的開發平台等揭示。

第1章 簡介

第2章 癌症疫苗的作用機制及技術創新

  • 個體遺傳型癌症疫苗的機制
  • 細胞癌症疫苗的機制
  • 神經節苷脂抗原為基礎的癌症疫苗的機制
  • 肽癌症疫苗的機制
  • 腫瘤宿主相互作用癌症疫苗的機制

第3章 對應癌症疫苗給藥的佐劑平台

第4章 全球癌症疫苗市場概要

  • 目前市場情況
  • 臨床實驗平台概要

第5章 對應個人化醫療的癌症疫苗:進步和可能性

第6章 為了接種人類乳突病毒(HPV)疫苗的公共計劃

第7章 全球癌症疫苗市場力學

  • 對市場成長的有利條件
    • 對癌症疫苗的需求擴大
    • 各國政府的經費資助與支援
    • 癌症疫苗開發的創新技術
    • 與個人化醫療對應的癌症疫苗的需求
    • 成為癌症疫苗開的順風的各種人口統計
  • 應該解決的課題

第8章 癌症疫苗今後的預測

第9章 全球性癌症疫苗臨床開發平台分析

  • 階段:未確認
  • 階段:研究
  • 階段:前臨床
  • 階段:臨床
  • 第一階段
  • 第I/II相
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 階段:登記前
  • 階段:登記完畢

第10章 上市的癌症疫苗的臨床表現

第11章 開發中斷或中止的癌症疫苗的臨床實驗平台

  • 沒有開發情形相關的報告
  • 中止
  • 中斷

第12章 癌症疫苗開發與上市相關的FDA的法律規範

  • 臨床試驗的早期階段和後期階段共通的注意事項
    • 患者數
    • 免疫反應的監視
    • 成為功效證據的生物標記
    • 為了促進免疫反應所使用的佐劑
    • 多種抗原疫苗
    • 最初施予病人癌症疫苗的緊接之後的病情進展/復發
    • 聯合治療和後續療法
  • 臨床試驗早期階段的注意事項
    • 投藥的開始投與藥計劃
    • 增壓器療法和維持療法
    • 用量增加
    • 在開發早期階段的單臂式實驗與隨機化第二階段實驗
  • 臨床試驗後期階段的注意事項
    • 早期階段的臨床試驗能得到了的安全性簡介
    • 評估項目
    • 統計上的問題
    • 控制上的問題
    • 延遲型的疫苗效果
    • 自我疫苗的實驗
    • 批審的加速相關法規

第13章 競爭環境:產業概要與產品的開發平台

  • Advaxis
  • Celldex Therapeutics
  • Dendreon Corporation
  • Galena Biopharma
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Inovio Pharmaceuticals
  • Merck
  • NeoStem Oncology
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • Peregrine Pharmaceuticals
  • Roche
  • Seattle Genetics

圖表清單

目錄

Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer.

With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory.

The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

The capital investments in many sections are required for the development and introduction of new cancer vaccines in market. The present market has handful of cancer vaccines for preventive and therapeutic categories. The limited options to choose from these products have significantly limited the pharmaceutical companies' profit margins. On the other hand, many companies are developing cancer vaccine for both of these categories. The introduction of new products will also alleviate the financial burden from the patients.

The cancer vaccine pipeline is expected to increase at tremendous rates in coming years. As large numbers of cancer vaccines are entering in various phases of clinical trials, due to which cancer market will soon observe a boost. However, the novelty of cancer vaccines makes it difficult for the standardization of clinical trials, because the criterias required to quantify its effectiveness are not completely discovered, this cause loss of valuable time. Moreover, the present day methods are standardized for conventional cancer therapeutic methods like chemotherapy, radiotherapy and surgery, which are not applicable for cancer vaccines due to their different mode of actions. In near future, researchers will find the solution for this problem and it will decrease the winding time.

“Global Cancer Vaccines Market & Pipeline Analysis” Report Highlights:

  • Global Cancer Market Overview
  • Personalized Cancer Vaccines: Progress & Possibilities
  • Platforms for Cancer Vaccines Delivery
  • Cancer Vaccines: Mechanism & Innovations
  • Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
  • Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
  • Marketed Cancer Vaccines: 12 Vaccines
  • Regulatory Framework for Cancer Vaccines Development & Marketing

Table of Contents

1. Introduction to Cancer Vaccines

2. Cancer Vaccines: Mechanism & Innovations

  • 2.1. Idiotype Cancer Vaccine Mechanism
  • 2.2. Cellular Cancer Vaccines Mechanism
  • 2.3. Ganglioside Antigens based Cancer Vaccines Mechanism
  • 2.4. Peptide Cancer Vaccine Mechanism
  • 2.5. Tumor Host Interaction Cancer Vaccine Mechanism

3. Adjuvants Platforms for Cancer Vaccines Delivery

4. Global Cancer Vaccines Market Overview

  • 4.1. Current Market Scenario
  • 4.2. Clinical Pipeline Overview

5. Personalized Cancer Vaccines: Progress & Possibilities

6. Public HPV Cancer Vaccination Program

7. Global Cancer Vaccines Market Dynamics

  • 7.1. Favorable Market Parameters
    • 7.1.1. Increasing Demand for Cancer Vaccines
    • 7.1.2. Government Funding & Support
    • 7.1.3. Innovative Technologies for Cancer Vaccine Development
    • 7.1.4. On Demand Personalized Cancer Vaccines
    • 7.1.5. Myriad of Demographs for Cancer Vaccine Development
  • 7.2. Issues to be Resolved

8. Future Prospects of Cancer Vaccines

9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country

  • 9.1. Phase: Unknown
  • 9.2. Phase: Research
  • 9.3. Phase: Preclinical
  • 9.4. Phase: Clinical
  • 9.5. Phase-I
  • 9.6. Phase-I/II
  • 9.7. Phase-II
  • 9.8. Phase-II/III
  • 9.9. Phase-III
  • 9.10. Phase: Preregistration
  • 9.11. Phase: Registered

10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country

11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country

  • 11.1. No Development Reported
  • 11.2. Discontinued
  • 11.3. Suspended

12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing

  • 12.1. Considerations for both Early and Late Phase Clinical Trials
    • 12.1.1. Patient Population
    • 12.1.2. Monitoring the Immune Response
    • 12.1.3. Biomarkers as Evidence of Efficacy
    • 12.1.4. Adjuvants Used To Stimulate Immune Response
    • 12.1.5. Multi-Antigen Vaccines
    • 12.1.6. Disease Progression/Recurrence Immediately or Shortly After The Initial Administration Of Cancer Vaccines
    • 12.1.7. Concomitant & Subsequent Therapies
  • 12.2. Considerations for Early Phase Clinical Trials
    • 12.2.1. Starting Dose & Dosing Schedule
    • 12.2.2. Booster & Maintenance Therapy
    • 12.2.3. Dose Escalation
    • 12.2.4. Single Arm Versus Randomized Phase 2 Trials In Early Development
  • 12.3. Considerations for Late Phase Clinical Trials
    • 12.3.1. Safety Profile from Early Phase Clinical Trials
    • 12.3.2. Endpoints
    • 12.3.3. Statistical Issues
    • 12.3.4. Control Issues
    • 12.3.5. Delayed Vaccine Effect
    • 12.3.6. Autologous Vaccine Trials
    • 12.3.7. Accelerated Approval Regulations

13. Competitive Landscape: Business Overview & Product Pipeline

  • 13.1. Advaxis
  • 13.2. Celldex Therapeutics
  • 13.3. Dendreon Corporation
  • 13.4. Galena Biopharma
  • 13.5. ImmunoCellular Therapeutics
  • 13.6. ImmunoGen
  • 13.7. Inovio Pharmaceuticals
  • 13.8. Merck
  • 13.9. NeoStem Oncology
  • 13.10. NewLink Genetics
  • 13.11. Northwest Biotherapeutics
  • 13.12. Novartis
  • 13.13. Peregrine Pharmaceuticals
  • 13.14. Roche
  • 13.15. Seattle Genetics

List of Figures:

  • Figure 1-1: Categorization & Function of Cancer Vaccines
  • Figure 2-1: Classification of Different Types of Cancer vaccines
  • Figure 4-1: Global Cancer Vaccines Market (US$ Billion), 2014-2020
  • Figure 4-2: Global Cancer Vaccines Market by Region (%), 2014 & 2020
  • Figure 4-3: Examples of Commercially Available Cancer Vaccines
  • Figure 4-4: Global Cancer Vaccines Clinical Pipeline by Phase (%), 2014
  • Figure 4-5: Global Cancer Vaccines Clinical Pipeline by Phase (Number), 2014
  • Figure 4-6: No Development Reported in Cancer Vaccines Pipeline by Phase (%), 2014
  • Figure 4-7: No Development Reported in Cancer Vaccines Pipeline by Phase (Number), 2014
  • Figure 4-8: Discontinued Cancer Vaccines in Pipeline by Phase (%), 2014
  • Figure 4-9: Discontinued Cancer Vaccines in Pipeline by Phase (Number), 2014
  • Figure 4-10: Suspended Cancer Vaccines in Pipeline by Phase (%), 2014
  • Figure 4-11: Suspended Cancer Vaccines in Pipeline by Phase (Number), 2014
  • Figure 5-1: Overview of Personalized Cancer Vaccines Development
  • Figure 5-2: Methodology for the Development of Personalized Cancer Vaccine
  • Figure 5-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
  • Figure 6-1: Prophylactic Cancer Vaccines Available for Different Serotypes of HPV
  • Figure 7-1: Factors Responsible for High Demand of Cancer Vaccines
  • Figure 13-1: Advaxis Clinical Pipeline
  • Figure 13-2: Celldex Therapeutics Clinical Pipeline
  • Figure 13-3: Galena Biopharma Clinical Pipeline
  • Figure 13-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 13-5: ImmunoGen Clinical Pipeline
  • Figure 13-6: Inovio Pharmaceuticals Clinical Pipeline
  • Figure 13-7: NewLink Genetics Corporation Clinical Pipeline
  • Figure 13-8: Northwest Biotherapeutics Clinical Pipeline
  • Figure 13-9: Peregrine Pharmaceuticals Clinical Pipeline
  • Figure 13-10: Seattle Genetics Clinical Pipeline

List of Tables:

  • Table 5-1: Different Types of Biomarkers for Personalized Cancer Vaccine Development
Back to Top